Essity AB Class A · OMXSTO:ESSITY_A

Essity AB Class A — Non-Deal Roadshow (2017)

29 slides from Essity AB Class A's roadshow presentation, 2017

  1. Slide 1: The Future Hygiene and Health Company

    Slide 1: The Future Hygiene and Health Company

    The Future Hygiene and Health Company

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncert

  3. Slide 3: Essity in Brief

    Slide 3: Essity in Brief

    Essity in Brief 101,238 SEK million in net sales 2016 11,992 SEK million in adjusted EBITA1) 2016 Presence in approximately 150 Number of employees2) 42,520 countries Note: 2016 figures exclude BSN medical, which will be consolidated as of April 3, 2017. 1) Excluding items affecting comparability. 2

  4. Slide 4: Essity’s Business

    Slide 4: Essity’s Business

    Essity’s Business  Leading global hygiene and health company  #1 or #2 position in around 90 countries in at least one product segment  Global market leader in incontinence products with TENA and in professional hygiene with Tork  Strong brands and market positions  Strong presence in emerging

  5. Slide 5: Key Investment Highlights

    Slide 5: Key Investment Highlights

    Key Investment Highlights  Operates in attractive markets supported by demographic trends  Leading market positions and strong brands  Strong presence in emerging markets  Successful innovations strengthen product offerings  BSN medical acquisition creates new growth platform  Track record of

  6. Slide 6: 2016 Net Sales

    Slide 6: 2016 Net Sales

    2016 Net Sales Essity (excluding BSN medical): SEK 101.2bn BSN medical: SEK 8.0bn1) Feminine Personal Care 7% Other Care Baby Care 33% 9% 4% Incontinence Wound Products Consumer Orthopedics 37% Care 34% 17% Tissue 41% 25% Professional Compression Therapy Hygiene 26% 1) BSN medical will be integrated

  7. Slide 7: 2016 Net Sales by Geography

    Slide 7: 2016 Net Sales by Geography

    2016 Net Sales by Geography Essity (excluding BSN medical): SEK 101.2bn BSN medical: SEK 8.0bn Middle East Latin Other Latin Africa America America 1% 4% 12% 9% Asia Asia 15% Pacific 15% 50% Europe Europe 57% 15% North 22% America North America 7

  8. Slide 8: 2016 Net Sales by Distribution Channel

    Slide 8: 2016 Net Sales by Distribution Channel

    2016 Net Sales by Distribution Channel Essity (excluding BSN medical): SEK 101.2bn BSN medical: SEK 8.0bn Healthcare Sector Other 11% 23% Hospitals / 38% Specialist Business to 26% Business Sanitary Shops 63% 16% Retail Trade 23% Pharmacies 8

  9. Slide 9: Global Market Positions

    Slide 9: Global Market Positions

    Global Market Positions Incontinence Products 1 Professional Hygiene 1 Consumer Tissue 2 Baby Care 4 Feminine Care 6 Medical Solutions 4 Source: The information has been compiled by Essity for presentation purposes based on statistics taken from external market sources including IRI, RISI, Price Han

  10. Slide 10: Addressable Hygiene and Health Market by Region

    Slide 10: Addressable Hygiene and Health Market by Region

    Addressable Hygiene and Health Market By Region North Europe America €26.1bn €33.2bn Asia Pacific €32.9bn Middle East & Africa €8.4bn Latin America €11.2bn Bubble Size: Market size Global Market Size: EUR ~112bn1) Source: The information has been compiled by Essity for presentation purposes based on

  11. Slide 11: Addressable Hygiene and Health Market by Category

    Slide 11: Addressable Hygiene and Health Market by Category

    Addressable Hygiene and Health Market By Category Incontinence Products Medical 8% Solutions 10% Consumer 37% Tissue Feminine 12% Care 12% Professional Hygiene 21% Baby Diapers Global Market Size: EUR ~112bn1) Source: The information has been compiled by Essity for presentation purposes based on sta

  12. Slide 12: Favorable Market Trends

    Slide 12: Favorable Market Trends

    Favorable Market Trends Growing and Aging Global Population Increased Disposable Income and Higher Living Standards Urbanization Increased Prevalence of Chronic Conditions Increased Access to Healthcare Increased Awareness about Health & Hygiene 12

  13. Slide 13: Usage of Hygiene Products

    Slide 13: Usage of Hygiene Products

    Usage of Hygiene Products High Potential in Markets with Low Penetration Incontinence Products Baby Diapers Feminine Care Tissue 500 2 500 300 25 400 2 000 250 20 300 200 1 500 15 150 200 1 000 10 100 100 500 5 50 0 North America West Europé Eastern Europé Latinamerica Asia 0 North America West Euro

  14. Slide 14: Strong Presence in Emerging Markets

    Slide 14: Strong Presence in Emerging Markets

    Strong Presence in Emerging Markets Latin Market Positions Emerging Markets accounts for America 35% of Net Sales 2016 Incontinence Products #1 Professional Hygiene #3 Asia Consumer Tissue #3 15% Feminine Care #1 Latin Baby Diapers #6 12% America Market Positions Asia 8% Incontinence Products #3 65%

  15. Slide 15: Strategic Framework

    Slide 15: Strategic Framework

    Strategic Framework VISION Dedicated to improving well-being through leading hygiene and health solutions MISSION To sustainably develop, produce, market and sell value-added products and services within hygiene and health OBJECTIVES Enable our Generate increased Enable more people Contribute to emp

  16. Slide 16: Win in Chosen Geographies and Categories

    Slide 16: Win in Chosen Geographies and Categories

    Win in Chosen Geographies and Categories 16

  17. Slide 17: BSN Medical: A Value Creating Acquisition

    Slide 17: BSN Medical: A Value Creating Acquisition

    BSN Medical A Value Creating Acquisition BSN medical develops, manufactures and sells products within wound care, compression therapy and orthopedics with well-known brands New growth platform and excellent strategic fit supporting Essity’s vision Expected annual synergies of at least EUR 30m High c

  18. Slide 18: Category Strategies

    Slide 18: Category Strategies

    Category Strategies Consumer Professional Incontinence Medical Baby Feminine Tissue Hygiene Products Solutions Care Care Branded Value Preferred Accelerate & New Growth Profitable Invest into Growth Choice in Lead Platform Choices Growth Professional Hygiene 18

  19. Slide 19: Innovate Bigger Brands

    Slide 19: Innovate Bigger Brands

    Innovate Bigger Brands Innovations Q1 2017 New Saba Re-launch of Libero TENA Flex with TENA Lady Familia® Good Night in Russia ConfioAir™ Discreet pH Balanceado 19

  20. Slide 20: Drive Efficiency

    Slide 20: Drive Efficiency

    Drive Efficiency Optimize Total Cost of Value Chain Optimize Capital Employed Drive Process and Resource Efficiency

  21. Slide 21: Tissue Roadmap

    Slide 21: Tissue Roadmap

    Tissue Roadmap Possibilities in creating value over the next 10 years Structural Potential Organic Potential Innovation Sourcing Footprint & Technology Manufacturing & Optimization Quality Strategy Efficiency Energy Upgrades Savings  Capacity expansion in selected markets to capture growth  Capex

  22. Slide 22: Digital Strategy

    Slide 22: Digital Strategy

    Digital Strategy Digital Digital Digital Capabilities Channels Products 22

  23. Slide 23: Essity Financial Profile (Excluding BSN Medical)

    Slide 23: Essity Financial Profile (Excluding BSN Medical)

    Essity Financial Profile (Excluding BSN Medical) Net Sales Adjusted EBITA1) SEKbn 101.2 SEKbn 12.0 98.5 10.6 9.5 88.0 2014 2015 2016 2014 2015 2016 Adjusted Organic Sales +6% +3% EBITA 10.8% 10.8% 11.8% Margin1) 1) Excludes items affecting comparability. 23

  24. Slide 24: Essity Financial Targets and Policies

    Slide 24: Essity Financial Targets and Policies

    Essity Financial Targets and Policies Annual Organic Adjusted Return on Capital Structure Dividend Sales Growth1) Capital Employed2) Policy Policy  To have an effective capital  Aims to provide long-term structure at the same time stable and rising dividends to its shareholders >3% >15% that the l

  25. Slide 25: Examples of Profitability Enhancing Initiatives

    Slide 25: Examples of Profitability Enhancing Initiatives

    Examples of Profitability Enhancing Initiatives  Value chain optimization  Tissue roadmap  Restructuring measures in France, Spain and the UK  Investments in Mexico and the UK  Cure or kill  Discontinued hygiene business in India  Exit Baby Care in Mexico  Value creating acquisitions  Wausa

  26. Slide 26: Financial Summary Q1 2017 vs Q1 2016

    Slide 26: Financial Summary Q1 2017 vs Q1 2016

    Essity (Excluding BSN Medical) Financial Summary Q1 2017 vs Q1 2016 Net Sales Organic Sales1) Adjusted EBITA2) SEK SEK 25,268m +1.0% 2,917m +4.2% +6% Adjusted EBITA Margin2) EPS Operating Cash Flow SEK 11.5% SEK 2.08 3,086m +20bp +60% 1) Sales which excludes exchange rate effects, acquisitions and d

  27. Slide 27: Summary and Key Takeaways

    Slide 27: Summary and Key Takeaways

    Summary and Key Takeaways  Operates in attractive markets supported by demographic trends  Leading market positions and strong brands  Strong presence in emerging markets  Successful innovations strengthen product offerings  BSN medical acquisition creates new growth platform  Track record of

  28. Slide 28: Q&A

    Slide 28: Q&A

    Q&A 28

  29. Slide 29

    Slide 29

Source: Internet Archive copy of essity.com

More decks from Essity AB Class A

All 40 Essity AB Class A decks